Methods for adjusting for bias due to crossover in oncology trials. (Q53138045)

11 May 2018

title

Methods for adjusting for bias due to crossover in oncology trials. (English)

1 reference

11 May 2018

1 reference

5

1 reference

11 May 2018

Juan Valle

6

1 reference

11 May 2018

author name string

K Jack Ishak

1

1 reference

11 May 2018

Irina Proskorovsky

2

1 reference

11 May 2018

Beata Korytowsky

3

1 reference

11 May 2018

Rickard Sandin

4

1 reference

11 May 2018

publication date

1 June 2014

1 reference

11 May 2018

published in

PharmacoEconomics

1 reference

11 May 2018

volume

32

1 reference

11 May 2018

issue

6

1 reference

11 May 2018

page(s)

533-546

1 reference

11 May 2018

Analysis of progression-free survival in oncology trials: some common statistical issues

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0145-Y

Issues in using progression-free survival when evaluating oncology products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0145-Y

Detecting an overall survival benefit that is derived from progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0145-Y

Estimating effects from randomized trials with discontinuations: the need for intent-to-treat design and G-estimation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0145-Y

Structural accelerated failure time models for survival analysis in studies with time-varying treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0145-Y

Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0145-Y

Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0145-Y

Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0145-Y

A causal proportional hazards estimator for the effect of treatment actually received in a randomized trial with all-or-nothing compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0145-Y

Parametric randomization-based methods for correcting for treatment changes in the assessment of the causal effect of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0145-Y

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0145-Y

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0145-Y

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0145-Y

Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0145-Y

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0145-Y

Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0145-Y

Limitation of inverse probability-of-censoring weights in estimating survival in the presence of strong selection bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0145-Y

Performance of statistical methods for analysing survival data in the presence of non-random compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-014-0145-Y

Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues

21 January 2018

1 reference

12 December 2020

Survival analyses of randomized clinical trials adjusted for patients who switch treatments

1 reference

12 December 2020

Estimating a treatment effect in survival studies in which patients switch treatment

1 reference

12 December 2020

When you look matters: the effect of assessment schedule on progression-free survival

1 reference

12 December 2020

10.1007/S40273-014-0145-Y

Identifiers

DOI

1 reference

11 May 2018

1 reference

11 May 2018